Category
Category I (research fields)
Ⅰ-1. Information science
| I-1-1 Bioinformatics/Systems biology | |
|---|---|
| Ⅰ-1-1-1 | Bioinformatics |
| Ⅰ-1-1-2 | Mathematical modeling/Simulation |
| Ⅰ-1-1-3 | Others |
| I-1-2 Artificial intelligence/Machine learning/Data science | |
|---|---|
| Ⅰ-1-2-1 | Big data analysis/Real-world evidence |
| Ⅰ-1-2-2 | Cancer patient data management and analysis |
| Ⅰ-1-2-3 | AI-based drug discovery |
| Ⅰ-1-2-4 | AI for cancer diagnosis |
| Ⅰ-1-2-5 | AI guidance (surgical/diagnostic support) |
| Ⅰ-1-2-6 | Others |
Ⅰ-2. Cancer prevention/Epidemiology
| I-2-1 Cancer prevention | |
|---|---|
| Ⅰ-2-1-1 | Cancer prevention (synthetic and natural compounds, dietary factors, vaccines) |
| Ⅰ-2-1-2 | Environmental factors/Infectious exposure |
| Ⅰ-2-1-3 | Anti-aging |
| Ⅰ-2-1-4 | Others |
| I-2-2 Epidemiology | |
|---|---|
| Ⅰ-2-2-1 | Cancer susceptibility/Molecular and genetic epidemiology |
| Ⅰ-2-2-2 | Cohort studies/Descriptive epidemiology/Cancer registry |
| Ⅰ-2-2-3 | Others |
Ⅰ-3. Carcinogenesis
| I-3-1 Aging and cancer | |
|---|---|
| Ⅰ-3-1-1 | Aging and cancer |
| Ⅰ-3-1-2 | Somatic mosaicism (clonal hematopoiesis etc.) |
| Ⅰ-3-1-3 | Natural-end cancer (Tenju-gann) |
| Ⅰ-3-1-4 | Others |
| I-3-2 Chemical carcinogenesis/Radiation carcinogenesis | |
|---|---|
| Ⅰ-3-2-1 | Carcinogens and risk assessment |
| Ⅰ-3-2-2 | DNA damage and carcinogenesis |
| Ⅰ-3-2-3 | Oxidative stress and cancer |
| Ⅰ-3-2-4 | Others |
| I-3-3 Infection-/Virus-/Inflammation-associated cancers | |
|---|---|
| Ⅰ-3-3-1 | Viral infection and cancer |
| Ⅰ-3-3-2 | Bacteria/Microbiome |
| Ⅰ-3-3-3 | Inflammation and cancer |
| Ⅰ-3-3-4 | Others |
Ⅰ-4. Molecular biology/Cell biology
| I-4-1 DNA replication/Cell cycle/Genomic instability | |
|---|---|
| Ⅰ-4-1-1 | Cell cycle/Checkpoint |
| Ⅰ-4-1-2 | DNA replication |
| Ⅰ-4-1-3 | DNA damage response and repair |
| Ⅰ-4-1-4 | Genomic instability |
| Ⅰ-4-1-5 | Others |
| I-4-2 Cancer genome/Genetics | |
|---|---|
| Ⅰ-4-2-1 | Genomic analysis |
| Ⅰ-4-2-2 | Clonal evolution |
| Ⅰ-4-2-3 | Chromosomal translocation/Gene rearrangement/Transposon |
| Ⅰ-4-2-4 | Extrachromosomal DNA |
| Ⅰ-4-2-5 | Others |
| I-4-3 Epigenomics/Epigenetics | |
|---|---|
| Ⅰ-4-3-1 | Epigenomic analysis |
| Ⅰ-4-3-2 | DNA methylation |
| Ⅰ-4-3-3 | Histone modification |
| Ⅰ-4-3-4 | Chromatin structure and remodeling |
| Ⅰ-4-3-5 | Non-coding RNAs |
| Ⅰ-4-3-6 | RNA splicing and RNA editing |
| Ⅰ-4-3-7 | Others |
| I-4-4 Oncogenes/Tumor-suppressor genes | |
|---|---|
| Ⅰ-4-4-1 | Oncogenes |
| Ⅰ-4-4-2 | Tumor-suppressor genes |
| Ⅰ-4-4-3 | Others |
| I-4-5 Intracellular signal transduction | |
|---|---|
| Ⅰ-4-5-1 | Cell proliferation and survival (RAS, PI3K, JAK/STAT etc.) |
| Ⅰ-4-5-2 | Differentiation and tissue homeostasis (Wnt, TGF-β, Hedgehog etc.) |
| Ⅰ-4-5-3 | Inflammation and immunity (NF-κB, IFN, cGAS–STING etc.) |
| Ⅰ-4-5-4 | Growth suppression (p53, Rb, p16, p21 etc.) |
| Ⅰ-4-5-5 | Transcription and translation regulation |
| Ⅰ-4-5-6 | Stress responses (UPR, ISR, ER stress etc.) |
| Ⅰ-4-5-7 | Others |
| I-4-6 Extracellular and Intercellular signal transduction | |
|---|---|
| Ⅰ-4-6-1 | Cell–cell signaling via adhesion |
| Ⅰ-4-6-2 | Paracrine signaling |
| Ⅰ-4-6-3 | Exosomes/Extracellular vesicles |
| Ⅰ-4-6-4 | Others |
Ⅰ-5. Hallmarks of cancer
| I-5-1 Characteristics of cancer cells and host cells | |
|---|---|
| Ⅰ-5-1-1 | Intracellular organelles/Phase separation |
| Ⅰ-5-1-2 | Glycosylation/Glycosyltransferases |
| Ⅰ-5-1-3 | Cell differentiation |
| Ⅰ-5-1-4 | Senescence/Immortalization/Telomeres |
| Ⅰ-5-1-5 | Cell death (apoptosis, ferroptosis etc.) |
| Ⅰ-5-1-6 | Autophagy |
| Ⅰ-5-1-7 | Cell competition |
| Ⅰ-5-1-8 | Cancer stem cells/Dormancy |
| Ⅰ-5-1-9 | Tumor plasticity/Heterogeneity |
| Ⅰ-5-1-10 | Cancer metabolism/Metabolomics |
| Ⅰ-5-1-11 | Cancer cachexia |
| Ⅰ-5-1-12 | Others |
| I-5-2 Invasion/Metastasis/Tumor microenvironment | |
|---|---|
| Ⅰ-5-2-1 | Cell adhesion and invasion |
| Ⅰ-5-2-2 | Extracellular matrix |
| Ⅰ-5-2-3 | EMT (epithelial–mesenchymal transition) |
| Ⅰ-5-2-4 | Circulating tumor cells |
| Ⅰ-5-2-5 | Angiogenesis |
| Ⅰ-5-2-6 | Tumor microenvironment (hypoxia, nutrient starvation etc.) |
| Ⅰ-5-2-7 | Metastasis models |
| Ⅰ-5-2-8 | Others |
| I-5-3 Experimental and alternative animal models | |
|---|---|
| Ⅰ-5-3-1 | Genetically engineered mouse models (GEMMs) |
| Ⅰ-5-3-2 | Animal carcinogenesis models |
| Ⅰ-5-3-3 | Patient-derived models |
| Ⅰ-5-3-4 | Cell culture systems (organoids etc.) |
| Ⅰ-5-3-5 | Other model organisms (zebrafish, Drosophila etc.) |
| Ⅰ-5-3-6 | Microphysiological systems (organ-on-a-chip etc.) |
| Ⅰ-5-3-7 | Others |
Ⅰ-6. Cancer immunity
| I-6-1 Cancer immunity | |
|---|---|
| Ⅰ-6-1-1 | Innate immunity and inflammation |
| Ⅰ-6-1-2 | Tumor antigens/Neoantigens |
| Ⅰ-6-1-3 | Antitumor immune response |
| Ⅰ-6-1-4 | Immune tolerance/Immune suppression/Immune evasion |
| Ⅰ-6-1-5 | Tumor immune microenvironment |
| Ⅰ-6-1-6 | Others |
Ⅰ-7. Therapeutic development
| I-7-1 Chemotherapy/Endocrine therapy | |
|---|---|
| Ⅰ-7-1-1 | Natural anticancer agents |
| Ⅰ-7-1-2 | Synthetic anticancer agents |
| Ⅰ-7-1-3 | Cytotoxic and endocrine therapies |
| Ⅰ-7-1-4 | Others |
| I-7-2 Molecular-targeted therapy | |
|---|---|
| Ⅰ-7-2-1 | Signal transduction inhibitors/Kinase inhibitors |
| Ⅰ-7-2-2 | Angiogenesis inhibitors/Metastasis inhibitors |
| Ⅰ-7-2-3 | Epigenetic modulators |
| Ⅰ-7-2-4 | Proteasome inhibitors/Protein degraders |
| Ⅰ-7-2-5 | Others |
| I-7-3 Immunotherapy | |
|---|---|
| Ⅰ-7-3-1 | Antibody therapy |
| Ⅰ-7-3-2 | Antibody engineering (ADCs, Bispecific Abs, BiTEs etc.) |
| Ⅰ-7-3-3 | Immune checkpoint inhibitors |
| Ⅰ-7-3-4 | Cancer vaccines |
| Ⅰ-7-3-5 | Photoimmunotherapy |
| Ⅰ-7-3-6 | Immune-related adverse events |
| Ⅰ-7-3-7 | Others |
| I-7-4 Cell therapy/Gene therapy/Regenerative medicine | |
|---|---|
| Ⅰ-7-4-1 | Immune cell therapy (CAR-T, T-cell therapy etc.) |
| Ⅰ-7-4-2 | Stem cell therapy |
| Ⅰ-7-4-3 | Designer cells/Exosomes |
| Ⅰ-7-4-4 | Gene therapy |
| Ⅰ-7-4-5 | Nucleic acid therapy |
| Ⅰ-7-4-6 | Others |
| I-7-5 Drug delivery system (DDS) | |
|---|---|
| Ⅰ-7-5-1 | Targeting DDS |
| Ⅰ-7-5-2 | Controlled release DDS |
| Ⅰ-7-5-3 | Others |
| I-7-6 Chemistry/Engineering | |
|---|---|
| Ⅰ-7-6-1 | Chemical biology |
| Ⅰ-7-6-2 | Functional materials |
| Ⅰ-7-6-3 | Others |
| I-7-7 Radiation therapy | |
|---|---|
| Ⅰ-7-7-1 | Radiotherapy/Particle therapy/BNCT |
| Ⅰ-7-7-2 | Radiosensitivity/Radiosensitization |
| Ⅰ-7-7-3 | Radioisotope therapy |
| Ⅰ-7-7-4 | Theranostics |
| Ⅰ-7-7-5 | Others |
| I-7-8 Surgical therapy | |
|---|---|
| Ⅰ-7-8-1 | Surgical intervention |
| Ⅰ-7-8-2 | Perioperative therapy |
| Ⅰ-7-8-3 | Multimodal treatment in surgery |
| Ⅰ-7-8-4 | Others |
| I-7-9 Drug resistance and its overcoming | |
|---|---|
| Ⅰ-7-9-1 | Drug sensitivity/Drug resistance |
| Ⅰ-7-9-2 | Sensitivity/Resistance to molecular targeted therapy |
| Ⅰ-7-9-3 | Drug-tolerant persister (DTP) cells |
| Ⅰ-7-9-4 | Others |
| I-7-10 Drug evaluation/Drug discovery technology | |
|---|---|
| Ⅰ-7-10-1 | Nonclinical pharmacology/Toxicology |
| Ⅰ-7-10-2 | Pharmacokinetics/Pharmacodynamics (PK/PD) |
| Ⅰ-7-10-3 | Sensitivity testing/Predictive biomarker |
| Ⅰ-7-10-4 | Drug repurposing/Drug repositioning |
| Ⅰ-7-10-5 | New drug modalities/New technologies |
| Ⅰ-7-10-6 | Others |
Ⅰ-8. Clinical trials/Translational research/Clinical research
| I-8-1 Clinical trials | |
|---|---|
| Ⅰ-8-1-1 | Clinical trials and related research |
| Ⅰ-8-1-2 | Translational research |
| Ⅰ-8-1-3 | Clinical trial design |
| Ⅰ-8-1-4 | Biostatistics |
| Ⅰ-8-1-5 | Regulatory science/Regulatory harmonization |
| Ⅰ-8-1-6 | Patient journey |
| Ⅰ-8-1-7 | Others |
| I-8-2 Diagnosis | |
|---|---|
| Ⅰ-8-2-1 | Pathological diagnosis/Digital pathology |
| Ⅰ-8-2-2 | Molecular pathology |
| Ⅰ-8-2-3 | Cancer imaging/Radiological diagnosis |
| Ⅰ-8-2-4 | Biomarker-based diagnosis |
| Ⅰ-8-2-5 | Genomic diagnosis/Panel sequencing |
| Ⅰ-8-2-6 | Expression-based diagnosis (mRNA, protein etc.) |
| Ⅰ-8-2-7 | Liquid biopsy |
| Ⅰ-8-2-8 | Others |
| I-8-3 Tumor-agnostic approach | |
|---|---|
| Ⅰ-8-3-1 | Genomic medicine/Precision medicine |
| Ⅰ-8-3-2 | Palliative care |
| Ⅰ-8-3-3 | Others |
Ⅰ-9. Cancer and society
| I-9-1 Cancer and society | |
|---|---|
| Ⅰ-9-1-1 | Cancer advocacy and outreach |
| Ⅰ-9-1-2 | Cancer survivorship |
| Ⅰ-9-1-3 | Advocacy/Patient engagement in research |
| Ⅰ-9-1-4 | Cancer education |
| Ⅰ-9-1-5 | Cancer policy |
| Ⅰ-9-1-6 | Others |
Category II (specific tumors)
Ⅱ-1. Specific tumors
| II-1-1 Specific tumors | |
|---|---|
| Ⅱ-1-1-1 | Brain tumors |
| Ⅱ-1-1-2 | Gastrointestinal tumors |
| Ⅱ-1-1-3 | Hepatobiliary and pancreatic tumors |
| Ⅱ-1-1-4 | Head and neck tumors/Thyroid tumors |
| Ⅱ-1-1-5 | Lung cancer/Thoracic tumors |
| Ⅱ-1-1-6 | Breast tumors |
| Ⅱ-1-1-7 | Gynecological tumors |
| Ⅱ-1-1-8 | Bone and soft tissue tumors |
| Ⅱ-1-1-9 | Urological tumors |
| Ⅱ-1-1-10 | Skin tumors |
| Ⅱ-1-1-11 | Hematological malignancies |
| Ⅱ-1-1-12 | Pediatric tumors/AYA-generation tumors |
| Ⅱ-1-1-13 | Rare cancer/Carcinoma of unknown primary |